Improvements in osteoporosis testing and care are found following the wide scale implementation of the Ontario Fracture Clinic Screening Program

An interrupted time series analysis

Dorcas E. Beaton, PhD\(^a\),b,c,d, Muhammad Mamdani, PharmD\(^b\),e,f,g, Hong Zheng, MSC\(^f\), Susan Jaglal, PhD\(^f\),h,i, Suzanne M. Cadarette, PhD\(^f\),g, Earl R. Bogoch, MD\(^f\),j, Joanna E. M. Sale, PhD\(^b\),l, Rebeka Sujic, MSc\(^k\),*, Ravi Jain, MHS\(^k\), the Ontario Osteoporosis Strategy Fracture Clinic Screening Program Evaluation Team

Abstract

We evaluated a system-wide impact of a health intervention to improve treatment of osteoporosis after a fragility fracture. The intervention consisted of assigning a screening coordinator to selected fracture clinics to identify, educate, and follow up with fragility fracture patients and inform their physicians of the need to evaluate bone health. Thirty-seven hospitals in the province of Ontario (Canada) were assigned a screening coordinator. Twenty-three similar hospitals were control sites. All hospitals had orthopedic services and handled moderate-to-higher volumes of fracture patients. Administrative health data were used to evaluate the impact of the intervention.

Fragility fracture patients (≥50 years; hip, humerus, forearm, spine, or pelvic fracture) were identified from administrative health records. Cases were fractures treated at 1 of the 37 hospitals assigned a coordinator. Controls were the same types of fractures at the control sites. Data were assembled for 20 quarters before and 10 quarters after the implementation (from January 2002 to March 2010). To test for a shift in trends, we employed an interrupted time series analysis—a study design used to evaluate the longitudinal effects of interventions, through regression modeling. The primary outcome measure was bone mineral density (BMD) testing. Osteoporosis medication initiation and persistence rates were secondary outcomes in a subset of patients ≥66 years of age.

A total of 147,071 patients were used in the analysis. BMD testing rates increased from 17.0% pre-intervention to 20.9% post-intervention at intervention sites (\(P<.01\)) compared with no change at control sites (14.9% and 14.9%, \(P=.33\)). Medication initiation improved significantly at intervention sites (21.6–23.97%; \(P=.02\)) but not at control sites (17.5–18.5%; \(P=.27\)). Persistence with bisphosphonates decreased at all sites, from 59.9% to 56.4% at intervention sites (\(P=.02\)) and more so from 62.3% to 54.2% at control sites (\(P<.01\)) using 50% proportion of days covered (PDC 50).

Significant improvements in BMD testing and treatment initiation were observed after the initiation of a coordinator-based screening program to improve osteoporosis management following fragility fracture.

Abbreviations: ARIMA = autoregressive integrated moving average (an interrupted time series analysis), BMD = bone mineral density, FCSP = Fracture Clinic Screening Program, ICES = Institute for Clinical Evaluative Sciences, OP = osteoporosis, PCP = primary care provider, PDC = proportion of days covered, PHAC = Public Health Agency of Canada.

Keywords: bone mineral density testing, compliance, coordinator, fragility fracture, osteoporosis, screening program, treatment initiation
1. Introduction

Fragility fractures are the most concerning presentation of osteoporosis (OP) and are a signal for increased fracture risk\[^{11-14}\] and increased mortality risk\[^{5}\] particularly after a hip fracture.\[^{6}\] Systematic reviews confirm the efficacy of bone-sparing medication (medication commonly used to treat OP) in reducing the risk of future fractures\[^{17-18}\] and have been integrated into clinical practice guidelines and position papers in Canada\[^{9,10}\] and abroad\[^{11-14}\] that recommend fracture-risk assessment and, when indicated, bone-sparing medication for the post-fragility fracture population. Despite this agreement, <20% of fragility fracture patients undergo testing or receive bone-sparing medication after their fragility fracture.\[^{15,16}\] Post-fracture programs have emerged to address this gap, with those using dedicated coordinators to facilitate guideline uptake having the best impact.\[^{17}\] Results from randomized trials support this model for testing and treatment after hip\[^{21}\] and wrist fractures\[^{22,23}\] with Morrish demonstrating a dose-response relationship between the intensity of the coordinator’s role and testing and OP outcomes.\[^{24}\] Program evaluations have suggested reduced fracture rates with these programs\[^{15,25}\] and even reduced mortality, attributing this to the initiation of proven bone-sparing medication.\[^{25}\] Even with the cost of a dedicated coordinator, the programs are cost-effective because of the costly hip fractures prevented\[^{25-30}\], the mean attributable direct health care costs for a hip fracture range from $36,929 (women) to $39,479 (men) in the first year.\[^{33}\]

Despite testing the benefit of a coordinator in clinical trials and implementation in various forms,\[^{14,32}\] we were unable to find studies that rigorously evaluated the relative effectiveness of a coordinator-based screening or liaison program versus usual care (no coordinator in place) in a wide-scale implementation of the model while attempting to control for risk of bias, or secular trends. In Ontario (population 13.8 million), a coordinator-based screening program was initiated in 2007 as part of a broader Ontario Osteoporosis Strategy.\[^{33}\] Twenty coordinators were placed in 37 hospitals that had higher volumes of these fragility fractures, and offered orthopedically managed outpatient fracture clinics. Another 23 similar hospitals existed at the time but were not assigned a coordinator due to budget limits (control hospitals in our analysis). All hospitals had orthopedic services and handled moderate-to-higher volumes of fracture patients. Hospitals chosen for a coordinator were selected based on the ability to integrate a coordinator into their post-fracture care, and proximity to another hospital site to allow sharing of a coordinator within a reasonable distance. Each hospital was approached by the Ministry of Health’s delegate regarding participating in the program and hospital-specific agreements were negotiated for the coordinator and their role. The coordinator’s role is to identify fragility fracture patients (defined as over 50 years of age with a low-trauma fracture) usually by case finding in the fracture clinic, and to facilitate investigation and interventions through the patient’s primary care provider (PCP). At the control hospitals, no specific additions were made to the fracture management program and any care was dependent on the initiative of the usual health care team and their practices.

The purpose of our study was to evaluate the impact of the implementation of the Fracture Clinic Screening Program (FCS) of the Ontario Osteoporosis Strategy on bone mineral density (BMD) testing, medication initiation, and medication persistence in the year after a fragility fracture.

2. Methods

2.1. Fracture Clinic Screening Program

The FCSP was started in January 2007 to case find (identify) fragility fracture patients (age 50 or over, and low energy fractures, that is, fractures due to slips, trips, or falls from standing height or less), to offer education to the patient and their PCP, to offer advice, and recommendations on testing needed for fracture-risk assessment, the role of Vitamin D and calcium, and to provide follow-up to those not on treatment at baseline to ensure they follow through with their PCP on suggestions made in clinic. In this model, much of the OP-related action needs to be taken by the PCP and the patients themselves (ie, investigation, intervention, and compliance).\[^{9,10}\] Coordinators are hired and trained centrally through Osteoporosis Canada to provide consistent, up-to-date information. Outcomes for this program have been reported and suggest up to 50% of patients will go on to have BMD testing, and 21% initiate prescription pharmacotherapy;\[^{34}\] reflecting advances over previous estimates of <10% to 20% having any discussion of bone health with their health care providers.

All sites had approval from their respective research ethics board for research use of the data in consenting patients. This specific analysis was also approved by the research ethics board of the senior investigator’s (DEB) home institution, St. Michael’s Hospital (REB# 08–304C).

2.2. Study design

This study made use of administrative health data for all insured Ontarians which are maintained at the Institute for Clinical Evaluative Sciences (ICES) in Toronto. ICES is a prescribed entity funded through the Ministry of Health and Long Term Care (single insurer in the province) and holding linked sociodemographic and health information for insured health events. It supports linked data across billing data for physicians and emergency room visits, diagnostic testing billings, hospital separations and, in those over the age of 65, prescription drug billings covered by the Ontario Drug Benefits Program. All persons eligible for universal health care in Ontario have health care expenses and activity tracked in these databases. The various data are linked across sources and longitudinally and are maintained at ICES. Data housed at ICES are widely used in health services research and are considered to be of high quality.\[^{15,36}\]

Fragility fracture cases from January 2002 (5 years, 20 quarters) before the program to March 2010 (3 years after the start of the program) were identified using the Public Health Agency of Canada’s (PHAC) case definition for a fragility fracture. This definition sought diagnoses codes (ICD9-CM and ICD10) for humerus, forearm, hip, spine, and pelvis fractures on billing data or hospital discharge records and restricts cases to those over age of 50\[^{36}\] with no similar fracture codes billed to that person’s file in the 6 months before that identification (ie, thus defining a “new” fracture). If billing codes related to a similar fracture were found in the past 6 months, we assumed the current episode of care was for the previous fracture.\[^{36}\] The PHAC case definition relies on the fracture type and age as being likely fragility fractures and does not specify low trauma etiology. This might attenuate intervention effects for programs like ours by including low and high trauma fractures; however, its
universal application across the population makes it the only means to compare before and after the program’s initiation in intervention hospitals or control.

Cases meeting PHAC fracture types were identified and restricted to those seen by orthopedic surgeons in the first 30 days post fracture, and seen at a moderate or high fragility fracture volume hospital (determined by the Ministry of Health and Long Term Care as having >350 fragility fracture cases per year). The cases were restricted to those over age of 50 and then separated into control and intervention hospitals based on whether that hospital had been assigned 1 of the 20 coordinators by the FCSP (intervention). The start time for the intervention varied over the ramp up of the program, so the individual start date was assigned time zero for each site and quarters defined as 3-month intervals before and after that date. Control hospitals had no such start date, and were assigned a start date by randomly selecting (without replacement) from the start dates of intervention hospitals. Quarters were then assigned again before and after that date. Each individual was then followed for outcome indicators for 1 year after the quarter in which their fracture visit occurred.

2.3. Administrative outcomes
2.3.1. Primary outcome: bone mineral density testing within 1 year of fracture. BMD testing was considered the primary outcome, as it is the most universal marker (ie, includes all eligible age groups, whereas medication use is only for those over 65) of post-fracture OP activity in our cohort.\(^{33}\) Billing for BMD testing in those eligible for BMD was calculated to create the primary outcome rate. Those who had a BMD test in the year before their fracture were not eligible for retesting, as their previous results would be considered adequate for fracture-risk assessment.

2.3.2. Secondary outcome: treatment initiation within 1 year of screening in those over 65 years of age. Treatment initiation was defined as the filling of a prescription for a bone-sparing agent in the year after a fragility fracture (ie, the first clinic visit after fracture).\(^{33}\) Those who had filled a prescription in the year before the fracture were excluded from the analysis on treatment initiation, as they were considered previously treated and would not reflect program impact. Medication billing was available for those 66 years and older, as all Ontarians 65 years and older are eligible for free prescription medications, including bone-sparing medication, through the Ontario Drug Benefits Program. In this analysis, we could therefore only include persons 66 years and older at time of fracture, to permit examination of the year before fracture to exclude those taking bone-sparing medication before the index fracture. Medications considered in this definition were: alendronate, risedronate, calcitonin, etidronate, teriparatide, and zoledronic acid.

2.3.3. Secondary outcome: persistence with taking medication. Persistence with medication was measured by calculating the proportion of days covered (PDC) by the drug prescriptions that were filled\(^{37,38}\) as an indicator of medication taking behavior or adherence. A PDC threshold of at least 80% (ie, the person filled enough prescriptions to comply with 80% of the usual dose)\(^{37,38}\) was required, as this has been shown to be the acceptable threshold for fracture prevention benefit.\(^{19}\) Compliance was calculated as the proportion of patients who initiated care in the year following their fracture who met the PDC threshold. We also report a lower threshold, PDC-50 (50% rather than 80%).

2.4. Analysis
2.4.1. Description of sample. The sample capture and characteristics were described using descriptive statistics.

2.4.2. Description of outcome rates. The sample description and the rates of the target outcomes described for all PHAC fracture cases seen in the control and intervention hospitals before and after program implementation were calculated and summarized. The numerator and denominator were defined only by those eligible for that outcome in that 1-year observation window. Thus, follow-up of an individual was censored at the 1-year post-screening visit to prevent late events (ie, BMD testing beyond 1 year) from favorably influencing rates.

2.4.3. Interrupted time series. To test for a shift in trends, we employed an interrupted time series analysis—a study design used to evaluate the longitudinal effects of interventions, through regression modelling. Since the interrupted time series is well suited for evaluation of effectiveness of population-level health interventions that have been implemented at a clearly defined point in time,\(^{39}\) we employed this study design to evaluate whether the program led to increased BMD testing, treatment initiation and persistence in the intervention group when compared with the control hospitals. Interventional autoregressive, integrated moving average (ARIMA) models were used to examine the impact of program initiation on rates of outcomes.\(^{41,42}\) Models were represented by their structural parameters and the best ARIMA model was selected based on the Schwarz-Bayesian criterion.\(^{43-45}\) Initial model specification was guided by visual inspection of correlograms, and ramp intervention functions were used to allow for more gradual intervention uptake. To test the appropriateness of model assumptions, we examined the autocorrelation, partial autocorrelation, and inverse autocorrelation functions. We performed the augmented Dickey-Fuller test to test for stationarity and examined the Ljung-Box \(\chi^2\) statistic at various lags to assess autocorrelation.

The anticipated shape of the impact of the intervention was either an immediate or delayed, yet sustained, higher rate of outcome after the intervention compared with before. The control hospitals were expected to experience no such change in trend but to continue as per pre-intervention trends. Analysis was carried out in SAS 9.3 (Cary, NC: SAS Institute).

3. Results
A cohort flowchart can be found in Figure 1. A final set of 147,071 cases were identified as having met the PHAC operational case definition for fragility fracture, age, and site criteria and had a visit date for the fracture before April 10, 2010 and were used in the analysis. At the intervention hospitals 109,173 fractures met the PHAC definition: 69,856 before the intervention and 39,317 after (some of which would have been in our program but not all). The control hospitals had 24,676 fractures before the program began and 13,222 fractures in the post-intervention period.

The demographic information is summarized in Table 1. Comparison of the pre-intervention group at the intervention hospitals and control hospitals demonstrated considerable similarities in terms of age, gender, and breakdown of fracture type.

3.1. Time series analysis
Table 2 summarizes the rates and their statistical significance for OP outcomes in the cases identified for the interrupted time series
3.2. **Primary outcome**

Average BMD testing rates increased significantly among intervention hospitals (from 17.0% before program implementation to 20.9% following implementation; \( P < .01 \), Table 2). The BMD testing rates at the control hospitals were stable at 14.9% (\( P = .33 \)). This is depicted graphically in Figure 2.

3.3. **Secondary outcomes**

Treatment initiation (pharmacotherapy dispensing in those over 65) showed statistically significant increases in intervention hospital (\( P < .02 \)) moving from 21.6% pre-implementation to 24.0% post-implementation, but there was no change in the control hospitals (17.5% and 18.5%, respectively, \( P = .27 \)). Medication persistence estimated by the PDC of either 80% or 50% declined in all groups from pre- to post-intervention period. Persistence in medication taking among intervention hospital cases dropped from 59.9% pre-intervention to 56.4% post-intervention (\( P = .02 \) at PDC50). At the PDC 80, the rates decreased from 45.8% to 40.1% (\( P < .001 \)). In control hospitals, a larger decrease in persistence (PDC 50) was found: 62.3% to 54.2% (\( P < .01 \)) or 47.6% to 38.5% (\( P < .01 \)) using a PDC-80 threshold.

4. **Discussion**

Interrupted time series analysis demonstrated a statistically significant increase in BMD testing rates in persons 50 years and older who had sustained a low-trauma fracture after the implementation of a province-wide FCSP compared with before implementation. Further, similar changes were not found in

---

Table 1

| Description of samples used in the interrupted time series analyses (control and intervention hospitals before and after implementation). |
|---------------------------------------------------------------|
| **Before implementation**                                      | **After implementation**            |
| **Control hospitals** N = 24,676 | **Intervention hospitals** N = 69,856 | **Control hospitals** N = 13,222 | **Intervention hospitals** N = 39,317 | **Total** N = 147,071 |
| Age at first post-fracture visit (visit date) | | | | |
| 50-65 | 6260 (25.4%) | 19,372 (27.7%) | 3,587 (27.1%) | 11,805 (30.0%) | 41,024 (27.9%) |
| 66-80 | 8679 (35.2%) | 24,985 (35.2%) | 4249 (32.1%) | 12,716 (32.3%) | 50,231 (34.2%) |
| 80+ | 9737 (39.5%) | 25,399 (37.1%) | 5266 (40.7%) | 14,794 (37.6%) | 55,816 (38.0%) |
| Sex | | | | | |
| Female | 18,569 (75.3%) | 51,922 (74.3%) | 9844 (74.5%) | 29,273 (74.5%) | 109,608 (74.5%) |
| Male | 6107 (24.7%) | 17,934 (25.7%) | 3378 (25.5%) | 10,044 (25.5%) | 37,463 (25.5%) |
| Fracture location | | | | | |
| Forearm only | 8895 (36.0%) | 28,178 (40.3%) | 4769 (36.1%) | 16,349 (41.6%) | 58,191 (39.6%) |
| Spine only | 577 (2.3%) | 2010 (2.9%) | 329 (2.5%) | 1150 (2.9%) | 4066 (2.8%) |
| Hip only | 11,349 (46.0%) | 28,828 (41.3%) | 5976 (45.2%) | 14,947 (38.0%) | 61,102 (41.5%) |
| Humerus only | 296 (12.1%) | 8548 (12.2%) | 1616 (12.2%) | 5336 (13.6%) | 18,496 (12.6%) |
| Pelvis only | 859 (3.5%) | 2292 (3.3%) | 530 (4.0%) | 1535 (3.9%) | 5216 (3.5%) |
| Living in rural setting | | | | | |
| No | 22,636 (91.7%) | 66,389 (95.0%) | 12,325 (93.2%) | 37,412 (95.2%) | 138,762 (94.4%) |
| Yes | 2033 (8.2%) | 3419 (4.9%) | 894 (6.8%) | 1892 (4.8%) | 8238 (5.6%) |
| Missing | 7 (0.0%) | 48 (0.1%) | \( \leq 5 \) (0.0%) | 13 (0.0%) | 71 (0.0%) |
| Long-term care resident | | | | | |
| No | 15,070 (61.1%) | 42,119 (60.3%) | 8171 (61.8%) | 23,578 (60.0%) | 88,938 (60.5%) |
| Yes | 2999 (12.2%) | 7507 (10.7%) | 1448 (11.0%) | 3852 (9.3%) | 15,606 (10.6%) |
| Missing | 6607 (26.8%) | 20,230 (29.0%) | 3603 (27.3%) | 12,087 (30.7%) | 42,527 (29.9%) |
| Has a physician | | | | | |
| No | 4,229 (17.1%) | 11,452 (16.4%) | 1847 (14.0%) | 5717 (14.5%) | 23,245 (15.8%) |
| Yes | 20,447 (82.9%) | 58,404 (83.6%) | 11,375 (86.0%) | 33,600 (85.5%) | 123,826 (84.2%) |

**Intervention hospital** = hospital offering osteoporosis screening coordinator services through the Ontario Osteoporosis Strategy Program (n = 37 hospitals), **Control hospital** = hospital with similar fracture volume, but without a Fracture Clinic Screening Program Coordinator.
observed outcome rates for pre- and post-intervention samples at intervention and control hospitals.

| Outcome                                           | Pre-intervention | Post-intervention | P values from ARIMA                  |
|---------------------------------------------------|------------------|-------------------|-------------------------------------|
|                                                  | Intervention     | Control           | Intervention hospitals: P < .01     |
| BMD testing rate, %                              | 17.0             | 14.9              | Control hospitals: P = .33          |
|                                                  | 20.9             | 14.9              |                                    |
| Bone sparing pharmacotherapy dispensing, %       |                  |                   |                                    |
|                                                  | 21.6             | 17.5              | Intervention hospitals: P < .02     |
|                                                  | 24.0             | 18.5              | Control hospitals: P = .27          |
| Persistence medication taking over 1 y in those initiating                                    |
| PDC50, %                                          |                  |                   |                                    |
|                                                  | 59.9             | 62.3              |                                    |
|                                                  | 56.4             | 54.2              |                                    |
|                                                    |                  |                   |                                    |
|                                                   | 45.8             | 47.6              |                                                    |
| PDC80, %                                           |                  |                   |                                    |
|                                                  | 40.0             | 38.5              |                                    |
| Outcomes of BMD testing, bone sparing pharmacotherapy dispensing, and persistence with medication taking (proportion of days covered [PDC] of 50% and 80% or better) in the year following the sentinel fracture are reported. P values are from the best model suited to the data in ARIMA analysis. |  
| Treatment included prescription bone sparing agents: alendronate, risedronate, calcitonin (on formulary at the time), etidronate, teriparatide, and zoledronic acid. This is only available in those over age 65, and here, in fracture at 66 or older to allow us to ascertain that they were not on medication at the time of fracture (ie, between age 65 and 66). |  
| Proportion days covered [PDC] >50% (PDC50) or 80% (PDC80); PDC80 is considered high adherence and optimal for fracture prevention; PDC50 is considered moderate. |  

Figure 2. Graphical depiction of trends for outcomes, divided into pre- and post-implementation phases (vertical line). Main lines (continuing before and after implementation) depict overall trends for intervention sites (blue) and control sites (red boxes).

A key feature in the quality of an interrupted time series analysis is the independent, unbiased ascertainment of outcomes,[48] and in our situation independence from the embedded coordinator him/herself. We used administrative data to allow greater objectivity across all subjects and less influence on outcome in those who were seen by the coordinator for follow-up information. The primary outcome was BMD testing billings, because they were available for all patients in the cohort (ie, not limited to those over age 66 years as was the case for medication initiation and persistence outcomes) and were recorded in the administrative health billings consistently over the study duration. An amendment to the government’s funding of BMD testing came into place in 2007 in an effort to curb overuse in low-risk patients. It was not intended to impact the testing of these higher-risk patients, and we believe that if it did, it would have done so equally in the intervention and control hospitals. BMD testing was therefore considered the most universal indicator of OP-related activity after a fragility fracture. Ramsay et al[48] suggest a set of 8 criteria for a high quality, interrupted time series analysis. Our study meets these criteria, with the exception that the observed impact of our intervention was more immediate and sustained than anticipated in our a priori hypothesis.
6. Limitations

There were 2 limitations to this study that should be acknowledged. First, the use of the PHAC case definition, though well accepted and recommended,[136] focuses on accurate coding for a probable or likely fragility fractures (type of fracture type and age), but it cannot ascertain the low-trauma nature of the fracture. All of our groups could therefore be a mix of high and low trauma. This would suggest that the focus of our message is on the trend, the shift that we observed and it significance, recognizing the actual point estimates could be attenuated by the inclusion of people who may have had high-trauma fractures (and would not be seen in our program) or indeed people whom the coordinators missed due to their being part time at each site. For the interrupted time series analysis the case definition had to be the same across all groups and we chose the PHAC as recommended for chronic disease surveillance in Canada.[136] The significance of our findings despite this attenuation builds confidence in our results.

A second limitation is the potential that there were uncontrolled biases in this analysis. Interrupted time series assumes populations of independent individuals, but there could have been clustering within hospitals in both our intervention and our control sites. Because we had so many sites, and we had control sites showing no advances in testing and treatment rates, we felt confident that the impact of any within hospital trends was not the cause of our findings.

Future research will continue to monitor the impact of the Ontario FCSP as changes are made. Recently a shift was made to allow the coordinators to order and book BMD testing allowing fracture-risk assessments to be communicated back to the PCP bringing more information to that visit. Future research can test for further impact of that program change. This shift will also allow risk stratified analyses based on the access to BMD test results and fracture-risk assessments that will be linked to the administrative data at ICES and provide more specific need-based analyses.

7. Conclusions

This study evaluated the impact of the implementation of a program designed to reduce a gap between clinical practice guidelines and front-line OP care following a fragility fracture. The program was implemented across 37 different hospitals in the province, reflecting some of the busiest fracture clinics in that publically funded health system. We demonstrated a positive, statistically significant impact of a coordinator, who acts as case finder, educator, and facilitator of bone-health screening and treatment in the fracture clinic setting, on BMD testing and OP treatment initiation. This study adds support to the growing body of knowledge on the effectiveness of fracture liaison service coordinator models[121-124,281] and is the first to use an interrupted time series analysis to evaluate the impact.

Acknowledgments

The authors gratefully acknowledge the support of Osteoporosis Canada, which implements the Ontario Osteoporosis Strategy Fracture Clinic Screening program on behalf of the MOHLTC. The authors also thank the Fracture Clinic Screening Program Evaluation Team for their contributions to the program and to overall evaluation of the program.

References

[1] Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003;14:879-83.
[2] Haentjens P, Autier P, Collins J, et al. Colles fracture, spine fracture, and subsequent risk of hip fracture in men and women. A meta-analysis. J Bone Joint Surg Am 2003;85-A:1936-43.
[3] Johnell O, Kanis JA, Odén A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004;15:175-9.
[4] Klotzbucher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39.
[5] Bluc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-21.
[6] Papaioannou A, Kennedy CC, Ioannidis G, et al. The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2009;20:703-14.
[7] Cranney A, Waldergill I, Zytaruk N, et al. Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev 2003;4:CD004523.
[8] Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:517-23.
[9] Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73.
[10] Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:51-34.
[11] Javid KS, Thiem A, Hill R. Implementation of and compliance with NICE guidelines in the secondary prevention of osteoporotic fractures in postmenopausal women. Ann R Coll Surg Eng 2008;90:213-5.
[12] Lewiecki EM, Watts NB. New guidelines for the prevention and treatment of osteoporosis. South Med J 2009;102:175-9.
[13] Akesson K, Marsh D, Mitchell PJ, et al. Capture the Fracture: A Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 2013;24:2135-52.
[14] Marsh D, Akesson K, Beaton DE, et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 2011;22:2051-65.
[15] Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis in Canada. CMAJ 2011;183:1035-44.
[16] Papaioannou A, Papaioannou A, Cranney A, et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 2006;35:293-305.
[17] Bell K, Strand H, Inder WJ. Effect of a dedicated osteoporosis health professional on screening and treatment in outpatients presenting with acute low trauma non-hip fracture: a systematic review. Arch Osteoporos 2014;9:167.
[18] Ganda K, Puech M, Chen JS, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int 2013;24:393-406.
[19] Sale JE, Beaton D, Posen J, et al. Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. Osteoporos Int 2011;22:2067-82.
[20] Gidwani S, Davidson N, Trgkijadas D, et al. The detection of patients with ‘fragility fractures’ in fracture clinic—an audit of practice with reference to recent British Orthopaedic Association guidelines. Ann R Coll Surg Eng 2007;89:147-50.
[21] Majumdar SR, Beaufre LA, Harley CH, et al. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med 2007;167:2110-5.
[22] Majumdar SR, Johnson JA, McAlester FA, et al. Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ 2008;178:569-75.
[23] Jaglal SB, Donescu OS, Bansod V, et al. Impact of a centralized osteoporosis coordinator on post-fracture osteoporosis management: a cluster randomized trial. Osteoporos Int 2012;23:87-95.
[25] Nakayama A, Major G, Holliday E, et al. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int 2016;27:873–9.

[26] Nakayama A, Major G, Holliday E, et al. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int 2016;27:873–9.

[27] Major G, Holliday E, et al. Targeted intervention reduces re-fracture rates in patients with incident non-vertebral osteoporotic fractures; a 4-year prospective controlled study. Osteoporos Int 2011; 22:849–58.

[28] Major G, Holliday E, et al. Targeted intervention reduces re-fracture rates in patients with incident non-vertebral osteoporotic fractures; a 4-year prospective controlled study. Osteoporos Int 2011; 22:849–58.

[29] Major G, Holliday E, et al. Targeted intervention reduces re-fracture rates in patients with incident non-vertebral osteoporotic fractures; a 4-year prospective controlled study. Osteoporos Int 2011; 22:849–58.

[30] Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011;96:1095–102.

[31] Nikitovic M, Wodchis WP, Krahn MD, et al. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. J Bone Joint Surg Am 2008;90:1197–205.

[32] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[33] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[34] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[35] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[36] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[37] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[38] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[39] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[40] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[41] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[42] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[43] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[44] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[45] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[46] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[47] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[48] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[49] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[50] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.

[51] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis program in post-fracture patients: results of a cost-effectiveness analysis conducted alongside a randomized trial. Osteoporos Int 2009;19:31–39.